244 related articles for article (PubMed ID: 33946962)
1. ATRX Alteration Contributes to Tumor Growth and Immune Escape in Pleomorphic Sarcomas.
Darmusey L; Pérot G; Thébault N; Le Guellec S; Desplat N; Gaston L; Delespaul L; Lesluyes T; Darbo E; Gomez-Brouchet A; Richard E; Baud J; Leroy L; Coindre JM; Blay JY; Chibon F
Cancers (Basel); 2021 Apr; 13(9):. PubMed ID: 33946962
[TBL] [Abstract][Full Text] [Related]
2. Targeted next-generation sequencing of cancer genes identified frequent TP53 and ATRX mutations in leiomyosarcoma.
Yang CY; Liau JY; Huang WJ; Chang YT; Chang MC; Lee JC; Tsai JH; Su YN; Hung CC; Jeng YM
Am J Transl Res; 2015; 7(10):2072-81. PubMed ID: 26692951
[TBL] [Abstract][Full Text] [Related]
3. Comprehensive screening of alternative lengthening of telomeres phenotype and loss of ATRX expression in sarcomas.
Liau JY; Lee JC; Tsai JH; Yang CY; Liu TL; Ke ZL; Hsu HH; Jeng YM
Mod Pathol; 2015 Dec; 28(12):1545-54. PubMed ID: 26428317
[TBL] [Abstract][Full Text] [Related]
4. Alternative lengthening of telomeres and loss of ATRX are frequent events in pleomorphic and dedifferentiated liposarcomas.
Lee JC; Jeng YM; Liau JY; Tsai JH; Hsu HH; Yang CY
Mod Pathol; 2015 Aug; 28(8):1064-73. PubMed ID: 26022452
[TBL] [Abstract][Full Text] [Related]
5. Differential nuclear ATRX expression in sarcomas.
Koelsche C; Renner M; Johann P; Leiss I; Sahm F; Schimmack S; Wardelmann E; Renker EK; Schirmacher P; Korshunov A; von Deimling A; Mechtersheimer G
Histopathology; 2016 Apr; 68(5):738-45. PubMed ID: 26291601
[TBL] [Abstract][Full Text] [Related]
6. Alternative lengthening of telomeres phenotype and loss of ATRX expression in sarcomas.
Ren X; Tu C; Tang Z; Ma R; Li Z
Oncol Lett; 2018 May; 15(5):7489-7496. PubMed ID: 29725455
[TBL] [Abstract][Full Text] [Related]
7. Exome Sequencing of Uterine Leiomyosarcomas Identifies Frequent Mutations in TP53, ATRX, and MED12.
Mäkinen N; Aavikko M; Heikkinen T; Taipale M; Taipale J; Koivisto-Korander R; Bützow R; Vahteristo P
PLoS Genet; 2016 Feb; 12(2):e1005850. PubMed ID: 26891131
[TBL] [Abstract][Full Text] [Related]
8. Leiomyosarcoma with alternative lengthening of telomeres is associated with aggressive histologic features, loss of ATRX expression, and poor clinical outcome.
Liau JY; Tsai JH; Jeng YM; Lee JC; Hsu HH; Yang CY
Am J Surg Pathol; 2015 Feb; 39(2):236-44. PubMed ID: 25229770
[TBL] [Abstract][Full Text] [Related]
9. Loss of atrx cooperates with p53-deficiency to promote the development of sarcomas and other malignancies.
Oppel F; Tao T; Shi H; Ross KN; Zimmerman MW; He S; Tong G; Aster JC; Look AT
PLoS Genet; 2019 Apr; 15(4):e1008039. PubMed ID: 30970016
[TBL] [Abstract][Full Text] [Related]
10. Alternative lengthening of telomeres phenotype in malignant vascular tumors is highly associated with loss of ATRX expression and is frequently observed in hepatic angiosarcomas.
Liau JY; Tsai JH; Yang CY; Lee JC; Liang CW; Hsu HH; Jeng YM
Hum Pathol; 2015 Sep; 46(9):1360-6. PubMed ID: 26190196
[TBL] [Abstract][Full Text] [Related]
11. Atrx deletion impairs CGAS/STING signaling and increases sarcoma response to radiation and oncolytic herpesvirus.
Floyd W; Pierpoint M; Su C; Patel R; Luo L; Deland K; Wisdom AJ; Zhu D; Ma Y; DeWitt SB; Williams NT; Lazarides AL; Somarelli JA; Corcoran DL; Eward WC; Cardona DM; Kirsch DG
J Clin Invest; 2023 Jul; 133(13):. PubMed ID: 37200088
[TBL] [Abstract][Full Text] [Related]
12. Loss of ATRX or DAXX expression and concomitant acquisition of the alternative lengthening of telomeres phenotype are late events in a small subset of MEN-1 syndrome pancreatic neuroendocrine tumors.
de Wilde RF; Heaphy CM; Maitra A; Meeker AK; Edil BH; Wolfgang CL; Ellison TA; Schulick RD; Molenaar IQ; Valk GD; Vriens MR; Borel Rinkes IH; Offerhaus GJ; Hruban RH; Matsukuma KE
Mod Pathol; 2012 Jul; 25(7):1033-9. PubMed ID: 22575867
[TBL] [Abstract][Full Text] [Related]
13. Constant p53 pathway inactivation in a large series of soft tissue sarcomas with complex genetics.
Pérot G; Chibon F; Montero A; Lagarde P; de Thé H; Terrier P; Guillou L; Ranchère D; Coindre JM; Aurias A
Am J Pathol; 2010 Oct; 177(4):2080-90. PubMed ID: 20884963
[TBL] [Abstract][Full Text] [Related]
14. Genomic and transcriptomic characterisation of undifferentiated pleomorphic sarcoma of bone.
Ali NM; Niada S; Brini AT; Morris MR; Kurusamy S; Alholle A; Huen D; Antonescu CR; Tirode F; Sumathi V; Latif F
J Pathol; 2019 Feb; 247(2):166-176. PubMed ID: 30281149
[TBL] [Abstract][Full Text] [Related]
15. ATRX mRNA expression combined with IDH1/2 mutational status and Ki-67 expression refines the molecular classification of astrocytic tumors: evidence from the whole transcriptome sequencing of 169 samples samples.
Cai J; Yang P; Zhang C; Zhang W; Liu Y; Bao Z; Liu X; Du W; Wang H; Jiang T; Jiang C
Oncotarget; 2014 May; 5(9):2551-61. PubMed ID: 24810474
[TBL] [Abstract][Full Text] [Related]
16. Loss of DAXX and ATRX are associated with chromosome instability and reduced survival of patients with pancreatic neuroendocrine tumors.
Marinoni I; Kurrer AS; Vassella E; Dettmer M; Rudolph T; Banz V; Hunger F; Pasquinelli S; Speel EJ; Perren A
Gastroenterology; 2014 Feb; 146(2):453-60.e5. PubMed ID: 24148618
[TBL] [Abstract][Full Text] [Related]
17. Experimental models of undifferentiated pleomorphic sarcoma and malignant peripheral nerve sheath tumor.
Bhalla AD; Landers SM; Singh AK; Landry JP; Yeagley MG; Myerson GSB; Delgado-Baez CB; Dunnand S; Nguyen T; Ma X; Bolshakov S; Menegaz BA; Lamhamedi-Cherradi SE; Mao X; Song X; Lazar AJ; McCutcheon IE; Slopis JM; Ludwig JA; Lev DC; Rai K; Torres KE
Lab Invest; 2022 Jun; 102(6):658-666. PubMed ID: 35228656
[TBL] [Abstract][Full Text] [Related]
18. Alternative lengthening of telomeres does exist in various canine sarcomas.
Kreilmeier T; Sampl S; Deloria AJ; Walter I; Reifinger M; Hauck M; Borst LB; Holzmann K; Kleiter M
Mol Carcinog; 2017 Mar; 56(3):923-935. PubMed ID: 27585244
[TBL] [Abstract][Full Text] [Related]
19. Alternative lengthening of telomeres and ATRX/DAXX loss can be reliably detected in FNAs of pancreatic neuroendocrine tumors.
VandenBussche CJ; Allison DB; Graham MK; Charu V; Lennon AM; Wolfgang CL; Hruban RH; Heaphy CM
Cancer Cytopathol; 2017 Jul; 125(7):544-551. PubMed ID: 28371511
[TBL] [Abstract][Full Text] [Related]
20. Potential application of genomic profiling for the diagnosis and treatment of patients with sarcoma.
Xu L; Xie X; Shi X; Zhang P; Liu A; Wang J; Zhang B
Oncol Lett; 2021 May; 21(5):353. PubMed ID: 33747210
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
